Protagonist Therapeutics Introduces PN-477 for Obesity Treatment

Protagonist Therapeutics has announced the nomination of its new development candidate, PN-477, aimed at treating obesity. PN-477 is a triple agonist peptide that targets GLP-1, GIP, and GCG receptors, available in both oral (PN-477o) and injectable (PN-477sc) forms. The company emphasizes the potential of PN-477 to balance body weight reduction with improved tolerability and effectiveness.

The triple agonist has undergone comprehensive preclinical evaluations, demonstrating promise in models of obesity and glycemic control. Phase I clinical studies for PN-477 are slated to begin in the second quarter of 2026. Protagonist anticipates that a combination of oral and injectable forms will provide a competitive edge in obesity treatment options.

Dr. Dinesh V. Patel, CEO of Protagonist, highlighted the potential of PN-477 as a groundbreaking therapeutic option, bridging the gap between existing treatments and enhancing efficacy with its unique triple activation mechanism.